<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01496430</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-491_304</org_study_id>
    <secondary_id>U1111-1125-1197</secondary_id>
    <nct_id>NCT01496430</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes</brief_title>
  <official_title>A Randomized, Double-Blind, Phase 3b Proof-of-Concept Study to Evaluate the Efficacy and Safety of TAK-491 Compared to Placebo When Used in Combination With Metformin in Subjects With Hypertension and Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the antihypertensive and antiglycemic effects, as
      well as the safety and tolerability of TAK-491 (azilsartan medoxomil), once daily (QD), in
      stage 1 hypertensive, type 2 diabetes mellitus (T2DM) participants whose glycemic control was
      inadequate on metformin alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study included a Screening Period of up to 4 weeks, which coincided with a 2-week
      single-blind, placebo Run-in Period, a 24 week Treatment Period, and a 2-week Follow-up
      Period. The duration of the study was approximately 30 weeks. The planned number of
      participants (n=450) was not reached; actual enrollment consisted of 105 particpants. Due to
      low enrollment this study was terminated early by Takeda.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business Decision; No Safety Or Efficacy Concerns. (See below)
  </why_stopped>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The change in trough systolic blood pressure measured at week 8 relative to baseline. The trough is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (HbA1c)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Sitting Clinic Diastolic Blood Pressure</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The change in trough diastolic blood pressure measured at week 8 relative to baseline. The trough is the average of the non-missing values of the 3 serial trough sitting diastolic blood pressure measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The change in 24-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The change in 24-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The change in daytime (6am to 10pm) mean systolic blood pressure measured week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The change in 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded during the first 12 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The change in 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded during the first 12 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Trough (22 to 24 Hours After Dosing) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The change in trough systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Trough (22 to 24 Hours After Dosing) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The change in trough diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Rescue Glycemic Therapy</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Percentage of participants requiring rescue glycemic therapy during study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Glycemic Rescue</measure>
    <time_frame>24 Weeks</time_frame>
    <description>The time to the first instance of participants requiring glycemic rescue during study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HbA1c</measure>
    <time_frame>Baseline and Weeks 2, 4, 6, 8, 12, 16 and 20</time_frame>
    <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at each week indicated relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose</measure>
    <time_frame>Baseline and Weeks 2, 4, 6, 8, 12, 16, 20, and 24</time_frame>
    <description>The change between the fasting plasma glucose value collected at each week indicated relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 6 and Week 24 in 2h Glucose During Oral Glucose Tolerance Testing (OGTT)</measure>
    <time_frame>Baseline and Weeks 6 and 24</time_frame>
    <description>The change between the glucose value collected at weeks 6 and 24 relative to baseline. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 6 and Week 24 in the Area Under the Plasma Concentration-time Curve (AUC) for Glucose During OGTT</measure>
    <time_frame>Baseline and Weeks 6 and 24</time_frame>
    <description>The change between the AUC for glucose at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 6 and Week 24 in AUC for Insulin During OGTT</measure>
    <time_frame>Baseline and Weeks 6 and 24</time_frame>
    <description>The change between the AUC for insulin at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 6 and Week 24 in AUC for C-peptide During OGTT</measure>
    <time_frame>Baseline and Weeks 6 and 24</time_frame>
    <description>The change between the AUC for C-peptide at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 6 and Week 24 in AUC for Insulin/Glucose Ratio During OGTT</measure>
    <time_frame>Baseline and Weeks 6 and 24</time_frame>
    <description>The change between the AUC for insulin/glucose ratio at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 6 and Week 24 in AUC for Glucagon During OGTT</measure>
    <time_frame>Baseline and Weeks 6 and 24</time_frame>
    <description>The change between the AUC for glucagon at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Hypertension</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azilsartan Medoxomil 40 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azilsartan Medoxomil 80 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan medoxomil</intervention_name>
    <arm_group_label>Azilsartan Medoxomil 40 mg QD</arm_group_label>
    <other_name>TAK-491</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azilsartan medoxomil</intervention_name>
    <arm_group_label>Azilsartan Medoxomil 80 mg QD</arm_group_label>
    <other_name>TAK-491</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Was male or female and ≥18 years.

          2. Had type 2 diabetes mellitus with HbA1c of ≥7.5 to ≤9.5% at Screening.

          3. Was treated with metformin alone (no treatment with any antidiabetic agents other than
             metformin within the 3 months prior to Screening) and was experiencing inadequate
             glycemic control. The participant should have received metformin monotherapy for ≥8
             weeks prior to Screening at a stable dose ≥1500 mg). Participants with a maximum
             tolerated dose (MTD) that was documented to be less than 1500 mg of metformin could
             also be enrolled if this dose had been stable for 8 weeks prior to Screening.

          4. Was treated with antihypertensive therapy and had a mean, trough, sitting clinic
             systolic blood pressure (SBP) ≥135 and &lt; 160 mm Hg on Day -1 (after washout of prior
             antihypertensive therapy) or the participant had not received antihypertensive
             treatment within 28 days before Screening and had a mean sitting clinic SBP ≥135 and &lt;
             160 mm Hg at the Screening Visit and on Day -1.

          5. Had clinical laboratory evaluations (including clinical chemistry, hematology, and
             complete urinalysis) within the reference range for the testing laboratory or results
             that were deemed not clinically significant in this participant population for
             inclusion in this study, by the investigator.

        Exclusion Criteria:

          1. Had a mean, trough, sitting clinic diastolic blood pressure (DBP) ≥ 100 mm Hg at Day
             -1.

          2. Had type 1 or poorly controlled type 2 diabetes mellitus (HbA1c &gt;9.5%) at Screening.

          3. Was taking or expected to take an excluded medication.

          4. Had a history of myocardial infarction, heart failure, unstable angina, coronary
             artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy,
             cerebrovascular accident, or transient ischemic attack.

          5. Had clinically significant cardiac conduction defects (for example, 3rd degree
             atrioventricular block, left bundle branch block, sick sinus syndrome, atrial
             fibrillation).

          6. Had hemodynamically significant left ventricular outflow obstruction due to aortic
             valvular disease.

          7. Had secondary hypertension of any etiology (e.g., renovascular disease,
             pheochromocytoma, Cushing's syndrome).

          8. Had renal dysfunction defined as estimated glomerular filtration rate (eGFR) &lt;60
             mL/min/1.73 m2 at Screening.

          9. Had albuminuria defined as &gt;200 mg/g at Screening.

         10. Had known or suspected unilateral or bilateral renal artery stenosis.

         11. Had unexplained microhematuria ≥3 RBCs/HPF or macrohematuria at Screening and
             confirmed on repeat testing.

         12. Treatment with antidiabetic agents (sulfonylureas, glucagon-like peptide-1 (GLP-1)
             analogues, dipeptidyl peptidase-4 (DPP-4) inhibitors, glinides, thiazolidinediones
             (TZDs), and/or insulin) other than metformin during the 3 months prior to Screening.

         13. Had hyperkalemia as defined by central laboratory normal reference range at Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Director, Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Green Valley</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hawaiian Gardens</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwalk</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evergreen Park</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Avon</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenfield</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Margate</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calabash</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lenoir</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Centerville</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Downingtown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fleetwood</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Richland Hills</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pearland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2011</study_first_submitted>
  <study_first_submitted_qc>December 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2011</study_first_posted>
  <results_first_submitted>May 14, 2014</results_first_submitted>
  <results_first_submitted_qc>April 20, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 6, 2015</results_first_posted>
  <last_update_submitted>April 20, 2015</last_update_submitted>
  <last_update_submitted_qc>April 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <keyword>Hypertension and Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 41 investigative sites in the United States from 09 January 2012 to 30 May 2013.</recruitment_details>
      <pre_assignment_details>Participants with a diagnosis of stage 1 essential hypertension and type 2 diabetes mellitus uncontrolled on metformin were enrolled equally in 1 of 3 treatment groups, once a day placebo, 40 mg or 80 mg TAK-491.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo QD</title>
          <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Azilsartan Medoxomil 40 mg QD</title>
          <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Azilsartan Medoxomil 80 mg QD</title>
          <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Major Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Principal Investigator Discretion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized Set includes all enrolled participants who were randomized via the Interactive Voice/Web Response System.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo QD</title>
          <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Azilsartan Medoxomil 40 mg QD</title>
          <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Azilsartan Medoxomil 80 mg QD</title>
          <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="105"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.1" spread="8.66"/>
                    <measurement group_id="B2" value="54.7" spread="7.63"/>
                    <measurement group_id="B3" value="55.8" spread="7.37"/>
                    <measurement group_id="B4" value="55.9" spread="7.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 45 and 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169.4" spread="9.81"/>
                    <measurement group_id="B2" value="169.8" spread="9.41"/>
                    <measurement group_id="B3" value="167.0" spread="12.30"/>
                    <measurement group_id="B4" value="168.8" spread="10.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93.41" spread="19.165"/>
                    <measurement group_id="B2" value="94.56" spread="20.084"/>
                    <measurement group_id="B3" value="92.33" spread="24.027"/>
                    <measurement group_id="B4" value="93.43" spread="21.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.50" spread="5.977"/>
                    <measurement group_id="B2" value="32.58" spread="5.475"/>
                    <measurement group_id="B3" value="32.94" spread="7.339"/>
                    <measurement group_id="B4" value="32.67" spread="6.255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Glycosylated Hemoglobin (HbA1c)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≤8.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;8.5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated Glomerular Filtration Rate (eGFR)</title>
          <units>ml/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87.86" spread="18.068"/>
                    <measurement group_id="B2" value="89.31" spread="15.631"/>
                    <measurement group_id="B3" value="89.72" spread="18.379"/>
                    <measurement group_id="B4" value="88.96" spread="17.253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated Glomerular Filtration Rate (eGFR) Categories</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>30 - &lt;60 mL/min/1.73 m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 - &lt;90 mL/min/1.73 m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥90 mL/min/1.73 m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Systolic Blood Pressure (SBP) Hypertension Severity Category</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>SBP &lt;140 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>140 ≤SBP &lt;160 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>160 ≤SBP &lt;180 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP ≥ 180 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Diastolic Blood Pressure (DBP) Hypertension Severity Category</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>DBP &lt; 90 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP ≥ 90 mm Hg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antihypertension Medication Within 28 Days</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Washout Required</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>21-Day Washout</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Week Washout</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Female Reproductive Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Postmenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgically Sterile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female of Childbearing Potential</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N/A (participant is male)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure</title>
        <description>The change in trough systolic blood pressure measured at week 8 relative to baseline. The trough is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Sitting Clinic Systolic Blood Pressure</title>
          <description>The change in trough systolic blood pressure measured at week 8 relative to baseline. The trough is the average of the non-missing values of the 3 serial trough sitting systolic blood pressure measurements.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Missing values were imputed using last observation carried forward.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="2.71"/>
                    <measurement group_id="O2" value="-10.2" spread="2.69"/>
                    <measurement group_id="O3" value="-13.6" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>Sequential testing was used to control for multiple comparisons. Azilsartan medoxomil 80 mg was first compared to placebo and if p-value ≤0.05 then azilsartaon medoxomil 40 mg was compared to placebo.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.067</p_value>
            <p_value_desc>Sequential testing was used to control for multiple comparisons. Azilsartan medoxomil 80 mg was first compared to placebo and if p-value ≤0.05 then azilsartaon medoxomil 40 mg was compared to placebo.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c)</title>
        <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 relative to baseline.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c)</title>
          <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 relative to baseline.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Missing values were imputed using last observation carried forward.</population>
          <units>percentage glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.174"/>
                    <measurement group_id="O2" value="-0.19" spread="0.174"/>
                    <measurement group_id="O3" value="0.07" spread="0.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.860</p_value>
            <p_value_desc>Sequential testing was used to control for multiple comparisons. Azilsartan medoxomil 80 mg was first compared to placebo and if p-value ≤0.05 then azilsartaon medoxomil 40 mg was compared to placebo.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.210</p_value>
            <p_value_desc>Sequential testing was used to control for multiple comparisons. Azilsartan medoxomil 80 mg was first compared to placebo and if p-value ≤0.05 then azilsartaon medoxomil 40 mg was compared to placebo.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Sitting Clinic Diastolic Blood Pressure</title>
        <description>The change in trough diastolic blood pressure measured at week 8 relative to baseline. The trough is the average of the non-missing values of the 3 serial trough sitting diastolic blood pressure measurements.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Sitting Clinic Diastolic Blood Pressure</title>
          <description>The change in trough diastolic blood pressure measured at week 8 relative to baseline. The trough is the average of the non-missing values of the 3 serial trough sitting diastolic blood pressure measurements.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Missing values were imputed using last observation carried forward.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="1.36"/>
                    <measurement group_id="O2" value="-5.4" spread="1.37"/>
                    <measurement group_id="O3" value="-5.8" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</title>
        <description>The change in 24-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</title>
          <description>The change in 24-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="2.25"/>
                    <measurement group_id="O2" value="-8.3" spread="2.15"/>
                    <measurement group_id="O3" value="-11.3" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</title>
        <description>The change in 24-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</title>
          <description>The change in 24-hour mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.28"/>
                    <measurement group_id="O2" value="-4.7" spread="1.22"/>
                    <measurement group_id="O3" value="-7.2" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</title>
        <description>The change in daytime (6am to 10pm) mean systolic blood pressure measured week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</title>
          <description>The change in daytime (6am to 10pm) mean systolic blood pressure measured week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="2.23"/>
                    <measurement group_id="O2" value="-9.0" spread="2.13"/>
                    <measurement group_id="O3" value="-11.7" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</title>
        <description>The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</title>
          <description>The change in daytime (6am to 10pm) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="1.25"/>
                    <measurement group_id="O2" value="-5.1" spread="1.20"/>
                    <measurement group_id="O3" value="-7.5" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</title>
        <description>The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</title>
          <description>The change in nighttime (12am to 6am) mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="2.68"/>
                    <measurement group_id="O2" value="-6.2" spread="2.57"/>
                    <measurement group_id="O3" value="-10.9" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</title>
        <description>The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring</title>
          <description>The change in nighttime (12am to 6am) mean diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.65"/>
                    <measurement group_id="O2" value="-3.2" spread="1.58"/>
                    <measurement group_id="O3" value="-7.2" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring</title>
        <description>The change in 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded during the first 12 hours after dosing.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring</title>
          <description>The change in 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded during the first 12 hours after dosing.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="2.40"/>
                    <measurement group_id="O2" value="-8.6" spread="2.29"/>
                    <measurement group_id="O3" value="-12.3" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring</title>
        <description>The change in 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded during the first 12 hours after dosing.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring</title>
          <description>The change in 12-hour mean systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded during the first 12 hours after dosing.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="1.37"/>
                    <measurement group_id="O2" value="-4.7" spread="1.31"/>
                    <measurement group_id="O3" value="-8.2" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Trough (22 to 24 Hours After Dosing) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring</title>
        <description>The change in trough systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Trough (22 to 24 Hours After Dosing) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring</title>
          <description>The change in trough systolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="2.80"/>
                    <measurement group_id="O2" value="-7.6" spread="2.67"/>
                    <measurement group_id="O3" value="-7.9" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Trough (22 to 24 Hours After Dosing) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring</title>
        <description>The change in trough diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Trough (22 to 24 Hours After Dosing) Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring</title>
          <description>The change in trough diastolic blood pressure measured at week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.63"/>
                    <measurement group_id="O2" value="-6.8" spread="1.57"/>
                    <measurement group_id="O3" value="-4.0" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Requiring Rescue Glycemic Therapy</title>
        <description>Percentage of participants requiring rescue glycemic therapy during study.</description>
        <time_frame>24 Weeks</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Requiring Rescue Glycemic Therapy</title>
          <description>Percentage of participants requiring rescue glycemic therapy during study.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7"/>
                    <measurement group_id="O2" value="25.7"/>
                    <measurement group_id="O3" value="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Glycemic Rescue</title>
        <description>The time to the first instance of participants requiring glycemic rescue during study.</description>
        <time_frame>24 Weeks</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Glycemic Rescue</title>
          <description>The time to the first instance of participants requiring glycemic rescue during study.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="21.57">Median and third quartile times to glycemic rescue were not observed.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="22.57">Median and third quartile times to glycemic rescue were not observed.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="17.14">Median and third quartile times to glycemic rescue were not observed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HbA1c</title>
        <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at each week indicated relative to baseline.</description>
        <time_frame>Baseline and Weeks 2, 4, 6, 8, 12, 16 and 20</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c</title>
          <description>The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at each week indicated relative to baseline.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Missing values were imputed using last observation carried forward.</population>
          <units>percentage glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=34, 35, 32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.072"/>
                    <measurement group_id="O2" value="0.05" spread="0.071"/>
                    <measurement group_id="O3" value="-0.06" spread="0.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=35, 35, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.093"/>
                    <measurement group_id="O2" value="-0.02" spread="0.093"/>
                    <measurement group_id="O3" value="0.29" spread="0.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=35, 35, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.123"/>
                    <measurement group_id="O2" value="-0.02" spread="0.123"/>
                    <measurement group_id="O3" value="0.24" spread="0.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=35, 35, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.137"/>
                    <measurement group_id="O2" value="-0.03" spread="0.138"/>
                    <measurement group_id="O3" value="0.23" spread="0.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=35, 35, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.171"/>
                    <measurement group_id="O2" value="-0.05" spread="0.171"/>
                    <measurement group_id="O3" value="0.29" spread="0.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=35, 35, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.171"/>
                    <measurement group_id="O2" value="-0.06" spread="0.171"/>
                    <measurement group_id="O3" value="0.16" spread="0.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=35, 35, 33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.167"/>
                    <measurement group_id="O2" value="-0.13" spread="0.168"/>
                    <measurement group_id="O3" value="0.09" spread="0.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose</title>
        <description>The change between the fasting plasma glucose value collected at each week indicated relative to baseline.</description>
        <time_frame>Baseline and Weeks 2, 4, 6, 8, 12, 16, 20, and 24</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Missing values were imputed using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose</title>
          <description>The change between the fasting plasma glucose value collected at each week indicated relative to baseline.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Missing values were imputed using last observation carried forward.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=34, 35, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.435"/>
                    <measurement group_id="O2" value="0.64" spread="0.429"/>
                    <measurement group_id="O3" value="1.03" spread="0.435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=35, 35, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="0.464"/>
                    <measurement group_id="O2" value="0.45" spread="0.464"/>
                    <measurement group_id="O3" value="0.81" spread="0.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=35, 35, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.445"/>
                    <measurement group_id="O2" value="0.28" spread="0.445"/>
                    <measurement group_id="O3" value="0.81" spread="0.451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=35, 35, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.368"/>
                    <measurement group_id="O2" value="0.34" spread="0.368"/>
                    <measurement group_id="O3" value="0.96" spread="0.373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=35, 35, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.417"/>
                    <measurement group_id="O2" value="0.09" spread="0.417"/>
                    <measurement group_id="O3" value="0.94" spread="0.423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=35, 35, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.379"/>
                    <measurement group_id="O2" value="0.17" spread="0.379"/>
                    <measurement group_id="O3" value="0.49" spread="0.384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=35, 35, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="0.438"/>
                    <measurement group_id="O2" value="0.01" spread="0.438"/>
                    <measurement group_id="O3" value="0.86" spread="0.444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=35, 35, 34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="0.459"/>
                    <measurement group_id="O2" value="-0.15" spread="0.459"/>
                    <measurement group_id="O3" value="0.48" spread="0.465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 6 and Week 24 in 2h Glucose During Oral Glucose Tolerance Testing (OGTT)</title>
        <description>The change between the glucose value collected at weeks 6 and 24 relative to baseline. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.</description>
        <time_frame>Baseline and Weeks 6 and 24</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 6 and Week 24 in 2h Glucose During Oral Glucose Tolerance Testing (OGTT)</title>
          <description>The change between the glucose value collected at weeks 6 and 24 relative to baseline. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6 (n=30, 30, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="0.555"/>
                    <measurement group_id="O2" value="-0.46" spread="0.556"/>
                    <measurement group_id="O3" value="-0.09" spread="0.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=25, 26, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.824"/>
                    <measurement group_id="O2" value="-1.66" spread="0.811"/>
                    <measurement group_id="O3" value="-3.94" spread="0.949"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 6 and Week 24 in the Area Under the Plasma Concentration-time Curve (AUC) for Glucose During OGTT</title>
        <description>The change between the AUC for glucose at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.</description>
        <time_frame>Baseline and Weeks 6 and 24</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 6 and Week 24 in the Area Under the Plasma Concentration-time Curve (AUC) for Glucose During OGTT</title>
          <description>The change between the AUC for glucose at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
          <units>mmol*hours/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6 (n=28, 29, 29)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="1.159"/>
                    <measurement group_id="O2" value="-1.01" spread="1.148"/>
                    <measurement group_id="O3" value="1.04" spread="1.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=23, 24, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.97" spread="1.339"/>
                    <measurement group_id="O2" value="-1.13" spread="1.308"/>
                    <measurement group_id="O3" value="-5.52" spread="1.471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 6 and Week 24 in AUC for Insulin During OGTT</title>
        <description>The change between the AUC for insulin at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.</description>
        <time_frame>Baseline and Weeks 6 and 24</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 6 and Week 24 in AUC for Insulin During OGTT</title>
          <description>The change between the AUC for insulin at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
          <units>pmol*hours/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6 (n=28, 31, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.4" spread="74.80"/>
                    <measurement group_id="O2" value="-26.1" spread="71.42"/>
                    <measurement group_id="O3" value="19.5" spread="74.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=21, 25, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63.3" spread="162.81"/>
                    <measurement group_id="O2" value="80.1" spread="149.88"/>
                    <measurement group_id="O3" value="477.0" spread="169.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 6 and Week 24 in AUC for C-peptide During OGTT</title>
        <description>The change between the AUC for C-peptide at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.</description>
        <time_frame>Baseline and Weeks 6 and 24</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 6 and Week 24 in AUC for C-peptide During OGTT</title>
          <description>The change between the AUC for C-peptide at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
          <units>nmol*hours/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6 (n=28, 31, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.051" spread="0.1779"/>
                    <measurement group_id="O2" value="-0.091" spread="0.1696"/>
                    <measurement group_id="O3" value="-0.138" spread="0.1780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=21, 25, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.449" spread="0.2323"/>
                    <measurement group_id="O2" value="0.182" spread="0.2138"/>
                    <measurement group_id="O3" value="0.155" spread="0.2444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 6 and Week 24 in AUC for Insulin/Glucose Ratio During OGTT</title>
        <description>The change between the AUC for insulin/glucose ratio at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.</description>
        <time_frame>Baseline and Weeks 6 and 24</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 6 and Week 24 in AUC for Insulin/Glucose Ratio During OGTT</title>
          <description>The change between the AUC for insulin/glucose ratio at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
          <units>pmol*hr/mmol</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6 (n=27, 29, 28)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.86" spread="5.777"/>
                    <measurement group_id="O2" value="1.73" spread="5.578"/>
                    <measurement group_id="O3" value="-0.75" spread="5.663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=20, 23, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.36" spread="14.823"/>
                    <measurement group_id="O2" value="1.05" spread="13.883"/>
                    <measurement group_id="O3" value="52.68" spread="14.976"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 6 and Week 24 in AUC for Glucagon During OGTT</title>
        <description>The change between the AUC for glucagon at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.</description>
        <time_frame>Baseline and Weeks 6 and 24</time_frame>
        <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo QD</title>
            <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Azilsartan Medoxomil 40 mg QD</title>
            <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Azilsartan Medoxomil 80 mg QD</title>
            <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 6 and Week 24 in AUC for Glucagon During OGTT</title>
          <description>The change between the AUC for glucagon at weeks 6 and 24 relative to baseline. AUC will be calculated based on measurements at 0, 30, 60 and 120 minutes. Oral glucose tolerance test measures glucose, insulin, C-peptide, insulin/glucose ratio, and glucagon through blood samples drawn at 0, 30, 60, and 120 minutes following consumption of a 75 g glucose beverage.</description>
          <population>The full analysis set included all randomized participants who took at least 1 dose of double-blind study medication. Observed cases.</population>
          <units>ng*hours/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 6 (n=27, 27, 27)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="9.34"/>
                    <measurement group_id="O2" value="27.1" spread="9.39"/>
                    <measurement group_id="O3" value="0.2" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=22, 23, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="8.51"/>
                    <measurement group_id="O2" value="12.0" spread="8.45"/>
                    <measurement group_id="O3" value="1.0" spread="9.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug, for up to 28 weeks.</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo QD</title>
          <description>Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 24 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Azilsartan Medoxomil 40 mg QD</title>
          <description>Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 24 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Azilsartan Medoxomil 80 mg QD</title>
          <description>Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 24 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Because of low enrollment in the study, the sample sizes in the results data do not allow for significant interpretation of the results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Director; Clinical Science</name_or_title>
      <organization>Takeda</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

